Congratulations to one of our medoncs Steve Yip, MD, MSc for achieving the Top 40 under 40 this year!!! Thanks for all you do for our patients and for helping to build transformative programs in precision oncology. Proud of you! Alberta Health Services UCalgaryMedicine avenuecalgary.com/top-40-under-4…

Thank you Avenue Calgary Magazine for an amazing Top 40 Under 40 award ceremony. I’m truly honoured and humbled to be in such a remarkable cohort of leaders in Alberta. Thanks to my family, friends and patients. Daniel Heng Alberta Health Services albertacancer AHS_CancerCare OWN.CANCER

Thanks so much Christy! I can’t thank you and albertacancer enough for your nomination. I’m always here for you and OWN.CANCER Together, we’re achieving amazing things in cancer care for our patients.

Thank you UCalgaryMedicine I am proud to work with amazing colleagues and friends at the TBCC and soon to be Arthur JE Child Cancer Centre OWN.CANCER AHS_CancerCare Alberta Health Services U Calgary

Amazing talk on T cell engagers in #ProstateCancer with many novel targets from Neeraj Agarwal, MD, FASCO Very excited to be involved in this research space #ESMO2024

silke gillessen presenting results from PEACE-3 trial of Enzalutamide vs Enzalutamide + Radium-223 in mCR #ProstateCancer Practice-changing data with rPFS 0.69 & OS 0.69 favouring Enza + Ra-223! UroToday.com OncoAlert Gil Morgan, MD ESMO - Eur. Oncology #ESMO24

In patients with mHSPC #prostatecancer randomized ph2 trial👉adding Lutetium-177 (Pluvicto) to docetaxel met primary end point👉significantly improved undetectable PSA at 48 weeks Outstanding talk by Arun Azad Congrats Arun, Michael Hofman ESMO - Eur. Oncology #ESMO24 OncoAlert UroToday.com

25% reduction in risk of death with periop durvalumab plus NAC compared to NAC in muscle invasive #bladdercancer This is practice changing Tom Powles ! #ESMO2024

Excellent talk by Dr. Saad on a new mCSPC #prostatecancer treatment option with darolutamide plus ADT with a significant rPFS benefit over ADT. This will allow our patients, who have borderline candidacy for chemo, to gain access to darolutamide in this setting #ESMO2024

Immunotherapy has its role in a select few #ProstateCancer pts with MMRd with impressive outcomes on Nivo/Ipi as presented by Dr. Mehra. We’re working to identify and characterize these pts, and we need to do better #ESMO24

Amazing work from the TALAPRO2 team Neeraj Agarwal, MD, FASCO with an amazing all comer OS benefit with tala + enza in mCRPC and detailed genomics analysis, particularly BRCAm Karim Fizazi We’re truly privileged to have contributed to this pivotal study!

Great talk from Prof. Dr Bono on ctDNA as a biomarker in lutetium PSMA in exploratory analysis from PSMAfore. Hi ctDNA associated with poor rPFS/OS, and ctDNA clearance associated with improved rPFS/OS

Our leader in #bladdercancer Nimira Alimohamed just knocked it out of the park with an outstanding talk on ctDNA in TCC at #gu25 So proud to work on biomarkers and outcomes in this field with Dr. Alimohamed and POET Oncology

🏆 Congratulations to Daniel Heng (Daniel Heng), Head of Medical Oncology at the Arthur J.E. Child Comprehensive Cancer Centre, on receiving the Yvonne Award 2025 in the Breakthrough Research category! Recognized for his transformative contributions to advancing cancer

An impactful trial PR.21 led by Dr. Kim Chi demonstrating no difference in rPFS between 177Lu-PSMA vs docetaxel in PSMA PET positive mCRPC. Proud to have contributed to this important Canadian #ProstateCancer trial at #esmo2025 #pluvicto #ESMO25

Impressive results from EMBARK demonstrating Enza combo reduced risk of death by > 40% vs ADT alone in patients with high risk #ProstateCancer #ESMO25

Proud to have participated in the biomarker driven CAPITELLO trial, presented by Dr. Fizazi, showing significant rPFS benefit with capi + abi vs pbo + abi in PTEN deficient mCSPC. Another biomarker challenge is on the horizon as elegantly highlighted by Elena Castro #ESMO25